Proactively manage your pharmacy inventory
Drug patents …
… from Kazakhstan to Kalamazoo
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Manage your formulary budget
Find generic entry opportunities
Anticipate generic drug launch
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Synthetic peptide inhibitors of HIV transmission|
|Abstract:||The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP-178 (SEQ ID:1) ptide corresponding to amino acids 638 to 673 of the HIV-1.sub.LAI gp41 protein, and fragments, analogs and homologs of DP-178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.|
|Inventor(s):||Bolognesi; Dani Paul (Durham, NC), Matthews; Thomas James (Durham, NC), Wild; Carl T. (Durham, NC)|
|Assignee:||Duke University (Durham, NC)|
Patent Claim Types:|
see list of patent claims
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Japan||2009213475||<disabled in preview>|
|South Korea||100355407||<disabled in preview>|
|Chile||2004001413||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.